Tag: cytokine release syndrome
-
ESMO Therapeutic Landscapes 2026: Understanding Toxicity in Multispecific Antibodies and Immune-Cell Engagers
Overview: Why toxicity matters in multispecific antibodies and immune-cell engagers The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity profiles of next-generation biologics. Multispecific antibodies and immune-cell engagers represent a rapidly advancing frontier in cancer therapy, offering the promise of simultaneous targeting of tumor antigens and immune cells.…
-
ESMO Therapeutic Landscapes: Toxicity and Safety Management of Multispecific Antibodies and Immune-Cell Engagers
Overview of ESMO Therapeutic Landscapes 2026 The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity and safety considerations surrounding multispecific antibodies and immune-cell engagers. Scheduled for February 18, 2026, this technical program brings together hematology-oncology clinicians, translational scientists, and pharmacovigilance experts to examine the real-world challenges of next-generation…
-
Addressing Infection Risks: Immune Complications in CAR T-Cell and Bispecific Antibody Therapies for Advanced Multiple Myeloma
Understanding the Shift in Multiple Myeloma Treatment Advances in multiple myeloma (MM) have ushered in a new era of immunotherapies, notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific antibody (BsAb) therapy. These approaches leverage the patient’s own immune system to target myeloma cells, often achieving deep and lasting responses where traditional therapies fall short.…